AbbVie Inc.'s Stock Analysis

AbbVie Reports Third-Quarter 2025 Financial Results and Dividend Increase

AbbVie Inc. reported third-quarter 2025 financial results, with diluted earnings per share (EPS) of $0.10 on a GAAP basis, representing an 88.6% decrease, and adjusted diluted EPS of $1.86, a decrease of 38.0%. Net revenues for the quarter reached $15.776 billion, up 9.1% from the previous year, driven by strong performance in the immunology and neuroscience portfolios, which saw increases of 11.9% and 20.2%, respectively. However, revenues from the oncology and aesthetics portfolios experienced slight declines. The company has raised its adjusted diluted EPS guidance for the full year to a range of $10.61 to $10.65, accounting for an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expenses incurred year-to-date.

Additionally, AbbVie announced a 5.5% increase in its quarterly cash dividend, raising it from $1.64 to $1.73 per share, effective February 2026. This reflects AbbVie's commitment to returning cash to shareholders, as the company has increased its dividend by over 330% since its inception in 2013. The company is also advancing its pipeline with several new drug applications and clinical trial results that may further enhance its market position.

Oct 31, 2025 07:51:43

AbbVie Reports Significant Expenses Impacting Earnings Guidance

AbbVie anticipates a $2.7 billion expense related to acquired IPR&D and milestones for the third quarter of 2025, which is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share by $1.50. The company has provided a full-year adjusted diluted earnings per share guidance range of $10.38 to $10.58, which now includes this expense.

The adjusted diluted earnings per share guidance for the third quarter of 2025 is projected to be between $1.74 and $1.78, reflecting the impact of the acquired IPR&D and milestones expense. AbbVie has clarified that while these expenses may arise from collaborations and licensing agreements, they cannot be reliably forecasted beyond the current quarter.

Oct 03, 2025 16:09:03

AbbVie Settles Litigation on Upadacitinib Generic Manufacturing

AbbVie has reached a settlement with all generic manufacturers that filed applications for generic versions of its drug upadacitinib, marketed as RINVOQ. As a result of this settlement and the accompanying license agreements, AbbVie expects that no generic versions of upadacitinib will enter the U.S. market before April 2037, assuming pediatric exclusivity is granted.

This resolution is significant for AbbVie as it protects the market exclusivity of RINVOQ, potentially impacting the company's revenue from this product. The settlement also mitigates risks associated with litigation and challenges to its intellectual property, which could influence investor confidence and stock performance.

Sep 11, 2025 07:30:54

AbbVie Reports Second-Quarter 2025 Financial Results and Guidance

AbbVie announced its financial results for the second quarter of 2025, reporting a diluted earnings per share (EPS) of $0.52 on a GAAP basis, a decrease of 32.5%, while adjusted diluted EPS increased by 12.1% to $2.97. The company achieved net revenues of $15.423 billion, marking a 6.6% increase. Key contributors to revenue included the immunology portfolio, which generated $7.631 billion, and the neuroscience portfolio, which brought in $2.683 billion. However, revenues from the aesthetics portfolio decreased by 8.1% to $1.279 billion, driven by declines in Botox Cosmetic and Juvederm sales. AbbVie also raised its adjusted diluted EPS guidance for the full year to a range of $11.88 to $12.08, which accounts for an unfavorable impact of $0.55 per share from acquired IPR&D and milestones expenses incurred year-to-date through Q2 2025.

Recent developments included FDA approvals for Rinvoq and Emrelis, as well as positive results from clinical trials for several products, including Qulipta and Rinvoq in new indications. AbbVie also announced its acquisition of Capstan Therapeutics, which will enhance its pipeline with a potential first-in-class therapy for autoimmune diseases. The company continues to advance its oncology portfolio, with significant progress reported at the ASCO Annual Meeting. Despite a recent setback with the VERONA trial for Venclexta, AbbVie remains focused on innovation and expanding its therapeutic offerings across various medical fields.

Jul 31, 2025 07:48:24

AbbVie Reports Second Quarter 2025 Earnings Guidance Update

AbbVie anticipates a pre-tax expense of $823 million related to acquired IPR&D and milestones for the second quarter of 2025, which is expected to reduce both GAAP and adjusted non-GAAP diluted earnings per share by $0.42. The company has not finalized its results for the quarter ending June 30, 2025, and these preliminary estimates may change as financial statement closing procedures are completed.

For the full year 2025, AbbVie has updated its adjusted diluted earnings per share guidance to a range of $11.67 to $11.87, incorporating the anticipated second quarter expenses. The adjusted diluted earnings per share guidance for the second quarter is projected to be between $2.84 and $2.88, excluding any additional expenses from acquired IPR&D and milestones that may occur later in the year.

Jul 03, 2025 13:07:55

AbbVie Adjusts EPS Guidance Due to Acquired Expenses

AbbVie Inc. has updated its earnings per share (EPS) guidance for the second quarter and full year of 2025, reflecting the impact of acquired in-process research and development (IPR&D) and milestones expense. For Q2 2025, the adjusted diluted EPS is now projected to be between $2.84 and $2.88, after accounting for an expense of $823 million. This is a decrease from the previously announced guidance that did not include these expenses.

For the full year 2025, the adjusted diluted EPS guidance is now set between $11.67 and $11.87, with the same $823 million expense factored in. The guidance excludes any further IPR&D and milestones expenses that may arise after Q2 2025, as these costs cannot be reliably predicted at this time.

Jul 03, 2025 13:07:55

AbbVie Reports Q1 2025 Financial Results and Guidance Update

AbbVie announced its financial results for the first quarter of 2025, reporting a diluted earnings per share (EPS) of $0.72 on a GAAP basis, which is a decrease of 6.5%. However, the adjusted diluted EPS increased by 6.5% to $2.46. The company achieved net revenues of $13.343 billion, reflecting an 8.4% increase from the previous year. The immunology portfolio saw significant growth, with global net revenues of $6.264 billion, while the aesthetics portfolio experienced a decline of 11.7% in net revenues to $1.102 billion. AbbVie raised its adjusted diluted EPS guidance for the full year 2025 to a range of $12.09 to $12.29, factoring in an unfavorable impact from acquired expenses.

In recent developments, AbbVie announced the election of CEO Robert A. Michael as chairman of the board, effective July 1, 2025. The European Commission granted marketing authorization for Rinvoq to treat giant cell arteritis, and AbbVie reported positive trial results for Elahere in treating ovarian cancer. Additionally, the company has entered into a collaboration with Xilio Therapeutics for developing new immunotherapies and submitted a Biologics License Application for trenibotulinumtoxinE. Furthermore, AbbVie has announced a license agreement with Gubra to develop a long-acting amylin analog for obesity treatment.

Apr 25, 2025 07:48:22

AbbVie Adjusts EPS Guidance Following Q1 2025 Expenses

AbbVie Inc. has updated its guidance for adjusted diluted earnings per share (EPS) for the first quarter and full year of 2025, incorporating expenses related to acquired IPR&D and milestones. For Q1 2025, the adjusted diluted EPS is now projected to be between $2.34 and $2.38, reflecting a decrease due to an expense of $248 million, which lowers the EPS by $0.13. For the full year, the adjusted diluted EPS guidance is set between $11.99 and $12.19, also accounting for the same expense.

The company noted that the updated guidance does not include any potential impact from future expenses related to acquired IPR&D and milestones that may occur beyond Q1 2025, as these cannot be reliably predicted. Additionally, the guidance does not take into account the effects of a licensing agreement with Gubra for the development of GUB014295, which was finalized after the first quarter of 2025.

Apr 03, 2025 16:13:07

AbbVie Announces Leadership Changes and Board Retirement Details

AbbVie has appointed CEO Robert A. Michael as chairman of the board, effective July 1, 2025, succeeding Richard A. Gonzalez, who has served in this role since the company's inception in 2013. The board expressed confidence in Michael's leadership, highlighting his extensive experience and contributions to AbbVie’s success, particularly in navigating the end of exclusivity for Humira in the U.S. Additionally, Glenn F. Tilton will retire from the board on the same date after serving as lead independent director from 2013 to 2024.

The transition in leadership comes as the company looks to build on its track record of success and continue delivering innovative medicines. While the press release emphasizes the positive aspects of the leadership change, it does not address any current financial challenges or market conditions that may impact AbbVie’s future performance. The absence of any mention of financial metrics or challenges suggests a focus on leadership continuity rather than a detailed financial outlook.

Feb 14, 2025 07:30:58

AbbVie Reports $56.334 Billion in Full-Year Revenues

AbbVie announced a full-year net revenue of $56.334 billion, marking an increase of 3.7% on a reported basis. The company's immunology portfolio generated $26.682 billion, while the oncology and neuroscience portfolios saw significant growth, with revenues of $6.555 billion and $8.999 billion respectively. Notably, Skyrizi and Rinvoq contributed to this growth with revenues of $11.718 billion and $5.971 billion, reflecting increases of 49.3% and 50.8% respectively. The fourth-quarter results also showed a revenue increase of 5.6% to $15.102 billion, driven by the immunology and oncology sectors. Adjusted diluted EPS for the fourth quarter was reported at $2.16, despite a GAAP diluted loss per share of $0.02 due to impairment charges related to emraclidine. 

Conversely, AbbVie faced challenges with the decline of Humira, which saw a significant drop in net revenues, decreasing by 49.1% to $1.682 billion in the fourth quarter. The aesthetics portfolio also experienced a downturn, with a reported revenue decrease of 5.2% to $1.298 billion. Additionally, the company recorded a substantial non-cash after-tax intangible asset impairment charge of $3.5 billion, reflecting the challenges faced in the development of emraclidine. Overall, while AbbVie demonstrated growth in several areas, the declines in key products and the impairment charge raised concerns about future performance.

Jan 31, 2025 07:42:37